PolyPeptide Group AG - Asset Resilience Ratio

Latest as of June 2025: 9.92%

PolyPeptide Group AG (PPGN) has an Asset Resilience Ratio of 9.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of PolyPeptide Group AG for a breakdown of total debt and financial obligations.

Liquid Assets

CHF76.69 Million

≈ $96.96 Million USD Cash + Short-term Investments

Total Assets

CHF773.07 Million

≈ $977.37 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how PolyPeptide Group AG's Asset Resilience Ratio has changed over time. See PPGN book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down PolyPeptide Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PPGN market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF76.69 Million	9.92%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF76.69 Million	9.92%

Asset Resilience Insights

Limited Liquidity: PolyPeptide Group AG maintains only 9.92% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PolyPeptide Group AG Industry Peers by Asset Resilience Ratio

Compare PolyPeptide Group AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	35.10%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Shandong Lukang Pharmaceutical Co Ltd SHG:600789	Drug Manufacturers - Specialty & Generic	0.01%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	Drug Manufacturers - Specialty & Generic	0.40%
Shandong Shanda Wit Science and Technology Co Ltd SHE:000915	Drug Manufacturers - Specialty & Generic	25.22%

Annual Asset Resilience Ratio for PolyPeptide Group AG (2018–2024)

The table below shows the annual Asset Resilience Ratio data for PolyPeptide Group AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.02%	CHF68.28 Million ≈ $86.32 Million	CHF756.58 Million ≈ $956.52 Million	-4.86pp
2023-12-31	13.89%	CHF95.71 Million ≈ $121.00 Million	CHF689.09 Million ≈ $871.19 Million	+7.37pp
2022-12-31	6.52%	CHF37.53 Million ≈ $47.45 Million	CHF575.78 Million ≈ $727.94 Million	-16.39pp
2021-12-31	22.91%	CHF136.30 Million ≈ $172.32 Million	CHF595.04 Million ≈ $752.29 Million	+18.33pp
2020-12-31	4.58%	CHF17.21 Million ≈ $21.76 Million	CHF375.98 Million ≈ $475.33 Million	-1.16pp
2019-12-31	5.74%	CHF17.51 Million ≈ $22.13 Million	CHF305.14 Million ≈ $385.78 Million	+2.20pp
2018-12-31	3.54%	CHF10.04 Million ≈ $12.69 Million	CHF283.83 Million ≈ $358.83 Million	--

pp = percentage points

About PolyPeptide Group AG

SW:PPGN Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$1.60 Billion

CHF1.27 Billion CHF

Market Cap Rank

#10156 Global

#126 in Switzerland

Share Price

CHF38.45

Change (1 day)

+0.26%

52-Week Range

CHF18.88 - CHF40.75

All Time High

CHF143.30